EI
QTTB icon

EAM Investors’s Q32 Bio QTTB Stock Holding History

EAM Investors’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,703
Closed -$567K – 362
2024
Q3 		$567K Buy
+12,703
New +$467K 0.08% 224

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

EAM Investors's QTTB Position: Q4 2024 in Review

EAM Investors sold out of Q32 Bio (QTTB) in Q4 2024, closing a stake of 12,703 shares — an estimated $567K sold.

EAM Investors first reported a position in QTTB in Q3 2024 and held it in 1 quarter. The position peaked at $567K in Q3 2024. 92 funds tracked by Wall St. Rank hold QTTB as of Q4 2024.

  • EAM Investors reported no remaining Q32 Bio position as of Q4 2024 after selling out during the quarter.
  • EAM Investors sold 12,703 Q32 Bio shares in Q4 2024, an estimated $567K.
  • EAM Investors first reported a position in Q32 Bio in Q3 2024 and held it in 1 quarter.
  • EAM Investors's Q32 Bio position peaked at $567K in Q3 2024.
  • 92 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2024.

Based on EAM Investors's 13F filing for Q4 2024, filed 13 Feb 2025.